December 22, 2014 7:02 AM ET


Company Overview of Polyphor Ltd

Company Overview

Polyphor Ltd. is a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs. Its products include POL6326, an antagonist of the chemokine receptor CXCR4 for stem cell transplantation, tissue repair, and combination treatments in oncology; POL7080, a pseudomonas specific antibiotic with a mode of action to treat pseudomonas infections; and POL6014, an inhaled inhibitor of human neutrophil elastase for the treatment of Alpha-1 antitrypsin deficiency, cystic fibrosis, and other lung diseases. The company also develops solutions for multiple myeloma. Its pipeline of macrocycles also targets leukemia and chronic obstructive pulmonary ...

Hegenheimermattweg 125

Allschwil,  4123


Founded in 1996


41 61 567 16 00


41 61 567 16 01

Key Executives for Polyphor Ltd

Co-Founder and Chief Scientific Officer
Chief Financial Officer
Chief Operating Officer
Head of Technology Platforms
Compensation as of Fiscal Year 2014.

Polyphor Ltd Key Developments

Polyphor Ltd Presents at UBS Global Healthcare Conference, May-21-2014 12:00 PM

Polyphor Ltd Presents at UBS Global Healthcare Conference, May-21-2014 12:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Jean-Pierre Obrecht, Co-Founder, Chief Executive Officer and Director.

Roche Joins Forces with Polyphor to Develop an Antibiotic

Roche announced that it had joined forces with Polyphor to develop an antibiotic to fight a superbug that is increasing disease as per recorded by the hospitals. The contract is signed by Roche regarding an exclusive worldwide licensing with Polyphor to develop and commercialise the latter's experimental antibiotic POL7080. The drug's target is the Pseudomonas aeruginosa bacteria, which can give rise to life-threatening infections and usually occurs in patients in hospital, as well as members of the broader public who have weakened immune systems. Pseudomonas aeruginosa accounts for one in every 10 hospital-acquired infections in the United States and is listed as one of the six most dangerous drug-resistant microbes. This disease is mainly caused at urinary tract, respiratory system, joints and bones, and digestive system. The disease is a major hazard for patients suffering with cancer, AIDS, severe burns, and chronic infections such as cystic fibrosis.

Polyphor Signs License Agreement with Roche

Polyphor Ltd. and Roche Holding Ltd. have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa. Both the companies are based in Switzerland. Under the terms of the agreement, Roche will make an upfront payment of CHF 35 million ($38.38 million) to Polyphor as well as payments upon reaching certain development, regulatory and commercial milestones, potentially up to CHF 465 million ($509.95 million). In addition, Polyphor is entitled to receive tiered double-digit royalties on product sales. Polyphor will retain the option to co-promote an inhaled formulation of POL7080 in Europe. The value of the deal was $548.33 million.

Similar Private Companies By Industry

Company Name Region
Alexion Pharma International Sàrl Europe
Nycomed SICAR S.C.A. Europe
Micro-SPHERE S.A. Europe
Oncalis AG Europe
Mepha Pharma AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Polyphor Ltd, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at